risk-assessment
| Topic | Replies | Views | Activity | |
|---|---|---|---|---|
| Control limit of Nitrosamines and N-nitroso compounds |
|
2 | 285 | July 8, 2024 |
| On the role of digital tools in nitrosamine risk assessment for drug substance and drug product manufacturing processes -Pub |
|
0 | 141 | June 13, 2024 |
| 🇰🇷 Case study on the Occurrence of Impurities in Pharmaceuticals (Focusing on NDMA Cases) |
|
0 | 211 | May 31, 2024 |
| 🇪🇺 EDQM - top 10 deficiencies observed in new CEP applications |
|
0 | 825 | March 14, 2024 |
| 🇺🇸 FDA CDER Generic Drug Forum (GDF) 2024 |
|
5 | 1191 | April 14, 2024 |
| Identifying the Risk of Formation of Nitrosamines and Other Potentially Mutagenic Impurities during API Manufacture Using In Silico Risk Assessment -Pub |
|
0 | 1129 | June 6, 2023 |
| Nitrosamine Risk Assessments in Oligonucleotides |
|
2 | 586 | August 10, 2023 |